The executive director and president of North American Pharmaceuticals at GlaxoSmithKline (GSK) is stepping down from his role towards the end of the year.
Chris Viehbacher stood down from his role on the company's board last month and will be leaving the company on 1 December to "pursue another opportunity".
GSK ceo Andrew Witty, said: "I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavours."